Skip to main content

Table 2 Outcome matrix

From: Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviews

Author Physical function Pain Spinal mobility Spinal stiffness Patient’s global assessment Peripheral joints/entheses Acute phase reactants Spine/hip radiograph Fatigue
SM-ARD trials
 Dougados (1994) [41] +,+ (DFI) +,+ (VAS) +,+ (Schober) +,+ (minutes) −/−
 Dougados (1999) [42] +,+ (DFI) +,+ (VAS) +,+ (Schober) +,+ (minutes) +,+ (VAS) +,+ (CRP) −/−
 Dougados (2001) [43] +,+ (BASFI) +,+ (VAS) +,+ (Schober) +,+ (minutes) +,+ (VAS) +,+ (CRP) −/−
 Van der Heijde (2005_2) [44] +,+ (BASFI) +,+ (VAS) +,+ (Schober) +,+ (minutes) +,+ (VAS) +,+ (BASDAI question 4) +,+ (CRP) −/−
 Barkhuizen (2006) [27] +,+ (BASFI) +,+ (VAS) +,+ (Schober) +,+ (minutes) +,+ (VAS) +,+ (CRP) −/−
Physical therapy trials
 Kraag (1990) [45] +,+ (TADLQ) +,+ (VAS) +,+ (Schober) +,+ (TADLQ) −/−
 Hidding (1993) [46] +,+ (DFI 0) +,+ (VAS) +,+ (Schober) +,+ (VAS) +,+ (VAS) +,+ (enthesitis index) −/−
 Helliwell [31] +,+/− (VAS) +,+ (Schober) +,+/− (VAS) −/−
 Van Tubergen (2001) [47] +,+ (BASFI) +,+ (VAS) +,+ (minutes) +,+ (VAS) −/−
 Sweeney (2002) [48] +,+ (BASFI) +,+ (SES) +,+ (BAS-G) −/−
 Analay (2003) [49] +,+ (BASFI) +,+ (VAS) +,+ (Schober) +,+ (minutes) −/−
 Codish (2005) [50] +,+ (BASFI) +,+ (VAS) +,+/− (Schober) −/−
 Fernandez-de-Las-Penas (2005) [51] +,+ (BASFI) +,+ (Schober) −/−
 Lim [30] +,+ (BASFI) +,+/− (VAS) +,+ (FFD) −/−
 Ince (2006) [52] +,+ (Schober) −/−
 Altan (2006) [53] +,+ (BASFI) +,+ (VAS) +,+ (Schober) +,+ (NRS) +,+ (NRS) −/−
DC-ART trials
 Dougados (1986) [54] +,+ (DFI) +,+ (VAS) +,+ (Schober) +,+ (minutes) +,+ (enthesitis index) +,+ (ESR) −/−
 Feltelius [28] +,+/− (VAS) +,+/− (Schober) +,+ (VAS) +,+ (VAS) +,+ (enthesitis index) +,+ (ESR) −/−
 Nissila (1988) [55] +,+ (VAS) +,+ (Schober) +,+ (minutes) +,+ (VAS) +,+ (22-joint count) +,+ (CRP) −/−
 Davis (1989) [56] +,+ (VAS) +,+ (occiput-to-wall distance) +,+ (VAS) +,+ (CRP) −/−
 Winkler (1989) [57] +,+ (VAS) +,+ (Schober) +,+ (hours) +,+ (VAS) +,+ (66-joint count) +,+ (ESR) −/−
 Corkill [58] +,+ (VAS) +,+ (occiput-to-wall distance) +,+ (VAS) +,+ (CRP) −/−
 Krajnc (1990) [59] +,+ (Schober)   −/−
 Taylor [34] +,+ (VAS) +,+ (Schober) +,+ (VAS) +,+/− (NRS) +,+/− (joint count) +,+ (CRP) +,+/− SIJ score
 Kirwan [29] +,− (HAQ) +,− (VAS) +,+ (Schober) +,+/− (VAS) +,– (VAS) +,+/− (44-joint count) −/−
 Clegg (1996) [60] +,+ (DFI) +,+ (VAS) +,+ (Schober) +,+ (minutes) +,+/− (NRS) +,+ (44-joint count) +,+ (CRP) −/−
 Altan [35] +,+ (DFI) +,+ (VAS) +,− (Schober) +,+ (minutes) +,+ (NRS) +,+ (enthesitis index) +,+ (CRP) −/−
 Braun [36] +,+ (BASFI) +,+/− (NRS) +,+ (BASMI) +,+/− (minutes) +,+ (NRS) +,+ (44-joint count) +,+ (CRP) −/− +,+/− (NRS)
 Gorman (2002) [61] +,+ (BASFI) +,+/− (VAS) +,+ (Schober) +,+ (minutes) +,+ (VAS) +,+ (66-joint count) +,+ (CRP) −/−
 Roychowdhury (2002) [62] +,+ (BASMI) +,+ (minutes) +,+ (CRP) −/−
 Schmidt (2002) [63] +,+ (DFI) +,+ (VAS) +,+ (Schober) +,+ (minutes) +,+ (enthesitis index) +,+ (CRP) −/−
 Brandt [37] +,+ (BASFI) +,+/− (NRS) +,+ (BASMI) +,+/− (NRS) +,+/− (66-joint count) +,+/− (CRP) −/− +,+/− (NRS)
 Davis (2003) [64] +,+ (BASFI) +,+/− (VAS) +,+ (Schober) +,+ (minutes) +,+ (VAS) +,– (68-joint count) +,+ (CRP) −/−
 Calin (2004) [65] +,+ (BASFI 0) +,+ (VAS) +,+ (BASMI) +,+ (minutes) +,+ (VAS) +,– (68-joint count) +,+ (CRP) −/− +,+ (VAS)
 Gonzalez-Lopez [38] +,+ (BASFI) +,+ (VAS) +,+ (VAS) +,+ (VAS) +,+ (44-joint count) +,− (ESR) −/−
 Marzo-Ortega (2005) [66] +,+ (BASFI) +,+ (VAS) +,+ (minutes) +,+ (enthesitis index) +,− (ESR) −/−
 Van der Heijde (2005_1) [44] +,+ (BASFI) +,+ (VAS) +,+ (BASMI) +,+ (VAS) +,+ (enthesitis Index) +,+ (CRP) −/−
 Van der Heijde [32] +,+ (BASFI) +,+ (VAS) +,+ (BASMI) +,+ (VAS) +,+ (VAS) +,+ (44-joint count) +,+ (CRP) −/−
 Van der Heijde (2006_2) [67] +,+ (BASFI) +,+ (VAS) +,+ (Schober) +,+ (VAS) +,+ (VAS) +,+ (70-joint count) +,+ (CRP) −/−
 Lambert (2007) [68] +,+ (BASFI) +,+ (VAS) +,+ (BASMI) +,+ (VAS) +,+ (VAS) +,+ (44-joint count) +,+ (CRP) −/−
 Inman (2008) [69] +,+ (BASFI) +,+ (VAS) +,+ (BASMI) +,+ (VAS) +,+ (VAS) +,+ (CRP) −/− +,+ (JESQ)
 Barkham (2010) [70] +,+ (BASFI) +,+ (VAS) −/−
 Inman (2010) [71] +,+ (BASFI) +,+ (BASMI) +,+ (BAS-G) +,+ (CRP) −/−
 Braun (2011) [72] +,+ (BASFI) +,+ (VAS) +,+ (BASMI) +,+/− (VAS) +,+ (VAS) +,+ (66-joint count) +,+ (CRP) −/−
 Dougados [39] +,+ (BASFI) +,+ (VAS) +,+ (BASMI) +,− (VAS) +,+ (CRP) −/−
 Navarro-Sarabia (2011) [73] +,+ (BASFI) +,+ (VAS) +,+ (BASMI) +,+ (VAS) +,+ (66-joint count) +,+ (CRP) −/− +,+/− (VAS)
 Hu [40] +,+ (BASFI) +,+ (VAS) +,+ (CRP) −/− +,+/− (VAS 0–10)
 Bao (2014) [74] +,+ (BASFI) +,+ (VAS) +,+ (BASMI) +,+ (CRP) −/− +,+ (JESQ)
 Huang (2014) [75] +,+ (BASFI) +,+ (VAS) +,+ (BASMI) +,+ (VAS) +,+ (VAS) +,+ (44-joint count) +,+ (CRP) −/−
  1. +,+ indicates that outcome was measured and fully reported
  2. +,+/− indicates that outcome was measured and partially reported (e.g., only the P value is given for the comparison)
  3. +,− indicates that outcome was measured but not reported
  4. − indicates that outcome was not measured
  5. Abbreviations: DFI Dougados functional index, VAS visual analogue scale, NRS numeric range scale, ESR erythrocyte sedimentation rate, CRP C-reactive protein, BASFI Bath Ankylosing Spondylitis Functional Index, TADLQ Toronto Activity of Daily Living Questionnaire, HAQ Health Assessment Questionnaire, BASRI Bath Ankylosing Spondylitis Radiology Index, SES Stanford Self-Efficacy Scale, BAS-G Bath Ankylosing Spondylitis Global Index, BASDAI Bath Ankylosing Disease Activity Index, SPARCC SpondyloArthritis Research Consortium of Canada, JESQ Jenkins Sleep Evaluation Questionnaire